Welcome to our dedicated page for Travere Therapeutics SEC filings (Ticker: TVTX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Travere Therapeutics, Inc. filings document a rare-disease biopharmaceutical issuer whose disclosures center on FILSPARI (sparsentan), operating results, FDA regulatory events, and public-company governance. Recent 8-K reports furnish quarterly and annual financial results and disclose regulatory events involving FILSPARI in focal segmental glomerulosclerosis and IgA nephropathy.
Proxy materials cover annual meeting voting, board matters, executive compensation, equity awards, and stockholder governance. The filing record also documents formal event reporting under the Exchange Act for product-regulatory updates and financial-condition disclosures.
Travere Therapeutics CEO Eric M. Dube reported multiple equity transactions. On January 31, 2026, he acquired 113,800 shares of common stock at $0 through restricted stock units and received an option for 303,600 shares at an exercise price of $33.095 per share.
On February 3, 2026, he sold 66,452 shares at $32.06 and 33,635 shares at $32.70 under a pre-arranged Rule 10b5-1 trading plan, which also covered tax obligations from vesting. After these transactions, he directly held 432,886 common shares and 303,600 stock options.
Travere Therapeutics’ chief medical officer, Jula Inrig, reported equity grants and a tax-related share sale. On 01/31/2026, she acquired 28,130 shares of common stock at $0 through restricted stock unit settlement, bringing her holdings to 114,441 shares before a later sale.
That same day she received an employee stock option for 75,000 shares of common stock at an exercise price of $33.095, expiring on 01/31/2036, with vesting over four years. On 02/03/2026, she sold 6,956 shares of common stock at $32.12 per share to cover tax withholding from the vested units, a mandated “sell to cover” transaction, not a discretionary trade. After the sale, she directly owned 107,485 common shares and 75,000 stock options.
Travere Therapeutics' Chief Financial Officer Christopher R. Cline reported equity compensation activity and a related share sale. On January 31, 2026, he acquired 28,130 shares of common stock for $0 upon settlement of restricted stock units and held 120,213 shares afterward.
That same day he received an employee stock option for 75,000 shares at an exercise price of $33.095, expiring on January 31, 2036, with one-fourth vesting after one year and the rest vesting in 36 monthly installments. On February 3, 2026, he sold 7,242 shares at $32.12 per share to cover tax withholding from the vested restricted stock units, leaving him with 112,971 directly owned shares; the filing notes this was a mandated “sell to cover” transaction, not a discretionary trade.
Travere Therapeutics, Inc. Chief Commercial Officer Peter Heerma reported equity transactions in company stock. On January 31, 2026, he acquired 26,120 shares of common stock at $0 per share in connection with restricted stock units, bringing his direct holdings to 139,133 shares.
That same day, he received an employee stock option grant for 69,640 shares at an exercise price of $33.095 per share, vesting over four years. On February 3, 2026, he sold 7,310 shares at $32.12 per share to cover tax withholding owed on vested restricted stock units. The sale was executed under a mandatory "sell to cover" arrangement and is not described as a discretionary trade. After this sale, he directly held 131,823 shares of Travere common stock.
Travere Therapeutics Chief Research Officer William E. Rote reported routine equity compensation and a planned share sale. On 01/31/2026 he acquired 20,090 shares of common stock for $0 through restricted stock units and received an employee stock option for 53,570 shares at an exercise price of $33.095 per share.
These options vest over time, with one-fourth vesting on the first anniversary of grant and the remainder in 36 monthly installments. On 02/03/2026 he sold 12,446 shares of common stock at $32.87 per share under a Rule 10b5-1 trading plan, and held 109,087 common shares and 53,570 options directly afterward.
Travere Therapeutics SVP and Chief Accounting Officer Calvin Sandra reported equity awards and a tax-related stock sale. On January 31, 2026, she received 15,180 shares of common stock through vested restricted stock units and an employee stock option for 20,160 shares at an exercise price of $33.095 per share.
On February 3, 2026, she sold 4,333 shares of common stock at $32.12 per share to cover tax withholding from the RSU settlement, a mandated "sell to cover" transaction rather than a discretionary trade. After these transactions, she directly owned 49,080 shares of common stock and 20,160 stock options.
Travere Therapeutics' chief legal officer, Elizabeth E. Reed, reported routine equity compensation and a related tax sale. On 01/31/2026 she received 25,110 shares of common stock for $0 as restricted stock units settled, bringing her direct holdings to 115,380 shares. On 02/03/2026, 7,175 shares were sold at $32.12 solely to cover tax withholding on the vesting; the company’s plan requires this mandated “sell to cover” transaction, so it was not a discretionary trade. She also received an employee stock option on 01/31/2026 for 66,960 shares at an exercise price of $33.095, vesting 25% after one year and the remainder in 36 monthly installments, giving her 66,960 options directly held.
Travere Therapeutics insider plans additional share sale under Rule 144. A person identified as Eric M. Dube has filed to sell 100,087 shares of common stock of Travere Therapeutics through Fidelity Brokerage Services on NASDAQ, with an approximate sale date of 02/03/2026 and an aggregate market value of $3,289,859.69. The filing notes 89,472,327 common shares outstanding.
The 100,087 shares were acquired on 02/02/2026 via restricted stock vesting from the issuer as compensation, with payment also dated 02/02/2026. Over the prior three months, the same seller completed two sales of Travere common stock totaling 8,135 and 51,865 shares, generating gross proceeds of $244,153.28 and $1,560,982.50.
A Rule 144 notice covers a planned sale of 12,446 shares of common stock of the issuer on 02/03/2026 through Fidelity Brokerage Services LLC on the NASDAQ, with an aggregate market value of $409,100.02. The filing reports that 89,472,327 shares of this class were outstanding.
The seller, William E. Rote, acquired these 12,446 shares on 02/02/2026 via restricted stock vesting from the issuer as compensation. The notice also discloses that he sold 60,000 common shares on 12/24/2025 for gross proceeds of $2,406,178.52.
Travere Therapeutics CEO Eric M. Dube reported planned option exercises and related stock sales under a Rule 10b5-1 trading plan adopted on June 16, 2025. On January 23 and January 27, 2026, he exercised employee stock options for a total of 60,000 shares of common stock at an exercise price of $15.46 per share and sold the same number of shares at weighted average prices of $30.0127 and $30.097, respectively. Following these transactions, he held 419,173 shares of Travere common stock directly, and continued to hold fully vested employee stock options with a $15.46 exercise price expiring on January 31, 2030, including positions of 171,865 and 120,000 options.